Atherosclerosis
Volume 196, Issue 1 , Pages 420-424 , January 2008

Lipoprotein-associated phospholipase A2 concentrations in plasma are associated with the extent of coronary artery disease and correlate to adipose tissue levels of marine n-3 fatty acids

  • Erik Berg Schmidt

      Affiliations

    • Department of Cardiology and Center for Cardiovascular Research, Aalborg Hospital, Århus University Hospitals, Sdr. Skovvej 15, 9100 Aalborg, Denmark
    • Corresponding Author InformationCorresponding author. Tel.: +45 99326899.
    • ,
  • Wolfgang Koenig

      Affiliations

    • Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, Ulm, Germany
    • ,
  • Natalie Khuseyinova

      Affiliations

    • Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, Ulm, Germany
    • ,
  • Jeppe Hagstrup Christensen

      Affiliations

    • Department of Nephrology, Aalborg Hospital, Århus University Hospitals, Denmark

Received 21 August 2006 ,Revised 15 November 2006 ,Accepted 17 November 2006.

References 

  1. Caslake MJ, Packard CJ. Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease. Curr Opin Lipidol. 2003;14:347–352
  2. Macphee CH, Nelson JJ. An evolving story of lipoprotein associated phospholipase A2 in atherosclerosis and cardiovascular risk prediction. Eur Heart J. 2005;26:107–109
  3. Tjoelker LW, Wilder C, Eberhardt C, et al. Antiinflammatory properties of platelet-activating factor acetylhydrolase. Nature. 1995;374:549–553
  4. Packard CJ, O’Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease: West of Scotland Coronary Primary Prevention Study Group. N Engl J Med. 2000;343:1148–1155
  5. Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation. 2004;110:1903–1908
  6. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high sensitive C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2004;109:837–842
  7. Oei H-HS , van der Meer I, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke. The Rotterdam Study. Circulation. 2005;111:570–575
  8. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J. 2005;26:137–144
  9. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Arch Intern Med. 2005;165:2479–2484
  10. O’Donoghue M, Morrow DA, Sabatine MS, et al. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in the PROVE-IT-TIMI 22 (Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction) trial. Circulation. 2006;113:1745–1752
  11. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol. 2006;26:1586–1593
  12. Blake GJ, Dada N, Fox JC, Manson JE, Ridker P. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol. 2001;38:1302–1306
  13. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106:2747–2757
  14. Schmidt EB, Arnesen H, De Caterina R, Rasmussen LH, Kristensen SD. Marine n-3 polyunsaturated fatty acids and cardiovascular disease. Part I: background, epidemiology, effect on risk factors and safety. Thromb Res. 2005;115:163–170
  15. Christensen JH, Skou HA, Fog L, et al. Marine n-3 fatty acids, wine intake, and heart rate variability in patients referred for coronary angiography. Circulation. 2001;103:651–657
  16. Schmidt EB, Pedersen JO, Varming K, et al. n-3 fatty acids and leukocyte chemotaxis. Effects in hyperlipidemia and dose–response studies in healthy men. Arterioscler Thromb. 1991;11:429–435
  17. Christensen JH, Christensen MS, Dyerberg J, Schmidt EB. Heart rate variability and fatty acid content of blood cell membranes: a dose–response study with n-3 fatty acids. Am J Clin Nutr. 1999;70:331–337
  18. Madsen T, Christensen JH, Blom M, Schmidt EB. The effect of n-3 fatty acids on serum concentrations of C-reactive protein: a dose–response study. Br J Nutr. 2003;89:517–522
  19. Hoogeveen RC, Ballantyne CM. PLAC test for identification of individuals at increased risk for coronary heart disease. Expert Rev Mol Diagn. 2005;5:9–14
  20. Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis. 2000;150:413–419
  21. Boyd HF, Fell SC, Hickey DM, et al. Potent, orally active inhibitors of lipoprotein-associated phospholipase A(2): 1-(biphenylmethyl-amidoalkyl)-pyrimidones. Bioorg Med Chem Lett. 2002;12:51–55
  22. Johnson A, Zalewski A, Janmohamed S, et al. Lipoprotein-associated phospholipase A2 activity, an emerging CV risk marker, can be inhibited in atherosclerotic lesions and plasma by novel pharmacologic intervention: the results of a multicenter clinical study. Circulation. 2004;110(Suppl. III):III-590
  23. Griffin BA. The effect of n-3 fatty acids on low density lipoprotein subfractions. Lipids. 2001;36(Suppl.):S91–S97
  24. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis. Biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol. 2005;25:923–931
  25. Calder PC. Polyunsaturated fatty acids and inflammation. Prostagland Leuk Essent Fatty Acids. 2006;75:197–202

PII: S0021-9150(06)00701-5

doi: 10.1016/j.atherosclerosis.2006.11.027

Atherosclerosis
Volume 196, Issue 1 , Pages 420-424 , January 2008

Article Tools